Estimation of annual probabilities of changing disability levels in Australians with relapsing-remitting multiple sclerosis

Anxiety, depression and fatigue at 5-year review following CNS demyelination

(2016) S. Simpson et al.   ACTA NEUROLOGICA SCANDINAVICA

Predictors of long-term disability accrual in relapse-onset multiple sclerosis

(2016) Vilija G. Jokubaitis et al.   ANNALS OF NEUROLOGY

Higher latitude is significantly associated with an earlier age of disease onset in multiple sclerosis

(2016) Chunrong Tao et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Role of genetic susceptibility variants in predicting clinical course in multiple sclerosis: a cohort study

(2016) Gongbu Pan et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Stressful life events and the risk of initial central nervous system demyelination

(2016) Alice Saul et al.   Multiple Sclerosis Journal

The impact of multiple sclerosis severity on health state utility values: Evidence from Australia

(2016) Hasnat Ahmad et al.   Multiple Sclerosis Journal

Stressful life events and the risk of initial central nervous system demyelination

(2016) Alice Saul et al.   Multiple Sclerosis Journal

The impact of multiple sclerosis severity on health state utility values: Evidence from Australia

(2016) Hasnat Ahmad et al.   Multiple Sclerosis Journal

Male Sex Is Independently Associated with Faster Disability Accumulation in Relapse-Onset MS but Not in Primary Progressive MS

(2015) Karen Ann Ribbons et al.   PLoS One

The Effect of Disease Modifying Therapies on Disease Progression in Patients with Relapsing-Remitting Multiple Sclerosis: A Systematic Review and Meta-Analysis

(2015) Georgios Tsivgoulis et al.   PLoS One

Estimating Time to Disease Progression Comparing Transition Models and Survival Methods-An Analysis of Multiple Sclerosis Data

(2013) Micha Mandel et al.   BIOMETRICS

Relating relapse and T2 lesion changes to disability progression in multiple sclerosis: a systematic literature review and regression analysis

(2013) Kyle Fahrbach et al.   BMC Neurology

Association between multiple sclerosis risk-associated SNPs and relapse and disability – a prospective cohort study

(2013) Rui Lin et al.   Multiple Sclerosis Journal

The economic impact of multiple sclerosis in Australia in 2010

(2013) Andrew J Palmer et al.   Multiple Sclerosis Journal

Mortality in patients with multiple sclerosis

(2013) A. Scalfari et al.   NEUROLOGY

Treatment experience, burden and unmet needs (TRIBUNE) in MS study: results from five European countries

(2012) Korinna Karampampa et al.   Multiple Sclerosis Journal

Smoking is associated with progressive disease course and increased progression in clinical disability in a prospective cohort of people with multiple sclerosis

(2009) Fotini Pittas et al.   JOURNAL OF NEUROLOGY

Cost-Effectiveness Analyses of Natalizumab (Tysabri®) Compared with Other Disease-Modifying Therapies for People with Highly Active Relapsing-Remitting Multiple Sclerosis in the UK

(2009) Ray Gani et al.   PHARMACOECONOMICS

Development and Validation of a Markov Microsimulation Model for the Economic Evaluation of Treatments in Osteoporosis

(2009) Mickaël Hiligsmann et al.   VALUE IN HEALTH

Transferability of Economic Evaluations Across Jurisdictions: ISPOR Good Research Practices Task Force Report

(2009) Michael Drummond et al.   VALUE IN HEALTH

Estimating time-to-event from longitudinal ordinal data using random-effects Markov models: application to multiple sclerosis progression

(2008) M. Mandel et al.   BIOSTATISTICS

Contribution of relapses to disability in multiple sclerosis

(2008) C. Hirst et al.   JOURNAL OF NEUROLOGY

Cost–effectiveness of natalizumab in multiple sclerosis

(2008) Trygve Holmoy et al.   Expert Review of Pharmacoeconomics & Outcomes Research